(P < 0.05).Serum IGF-I as well as IGFBP-3 were increased in the manifest hyperthyroid group, to 157% (P < 0.001) and 129% (P < 0.05)respectively, whereas DHEAS levels did not change in either premenopausal patient group. In postmenopausal women BMD was significantly reduced both in the subclinical hyperthyroid group (spine to 90% and femoral neck to 88%; P < 0.05), as well as in the hyperthyroid group (spine to 78% and femoral neck to 86%; P < 0.01). In contrast to premenopausal women, serum IGF-I and IGFBP-3 did not change in the two groups who were postmenopausal and serum DHEAS levels were reduced to 58% (P < 0.001) in both postmenopausal groups with subclinical as well as overt hyperthyroidism. In the same two groups of patients, serum IGF-I and DHEAS levels correlated with BMD (femoral neck; both r = 0.50, P < 0.05). In conclusion, women with a solitary autonomous thyroid nodule with subclinical hyperthyroidism have reduced BMD only if they are postmenopausal. This is probably due to the effect of subtle increases in thyroid hormone production together with lack of oestrogen protection of the skeleton. But 
Introduction
In a previous study (1) we found reduced bone mineral density (BMD) in postmenopausal women with endo¬ genous subclinical hyperthyroidism. As BMD did not correlate with thyroid hormone levels it was assumed that some additional risk factors might play a role in these cases.
Growth hormone (GH)-dependent insulin-like growth factor-I (IGF-I) is involved in bone formation and maintenance (2, 3) . However, the relationship between IGF-I levels, BMD and the development of osteoporosis is still not clear (4, 5) .
Recently, a relationship was suggested between serum dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS) levels and the production of IGF-I (6), raising the possibility that DHEA represents a physiological regulator of IGF-I and IGF-binding protein-3 (IGFBF-3). It has been argued that especially adrenal-derived DHEAS plays an important role in preserving bone mass and decreased production of DHEAS may contribute to the development of postmenopausal osteoporosis (7) (8) (9) (10) .
Serum levels of IGF-I and DHEAS decline with age (3, 4-3 ±2-2 4-0 ±1-4 4-8 ±1-6 3-3 ±1-3 1-9*" ±0-9 1-9*** ±0-9 (Table 3) .
BMD of the femoral neck correlated positively to serum IGF-I levels in the 32 postmenopausal subjects with endogenous subclinical hyperthyroidism (r 
Discussion
In previous studies (16) The present study extends and supports our previous findings (1) (2) . IGF-I present in the bone may be derived from local production from osteoblasts (17) , which seems GH-independent, or hepatic production, which seems GHdependent (17 (4, 21) . Thyroid hormones stimulate IGF-I production of bone cells in vitro (22) . Recently increased IGF-I levels were found in thyrotoxic patients (23) In the circulation IGF-I is bound to binding proteins (25) . IGFBF-3 is the major circulating binding protein, the production of which is regulated by GH (26) . probably acts as a reservoir for circulating IGF-I. It correlates with IGF levels, and seems less age-dependent than IGF-I (27) . In the present study 
